益生菌制剂对非酒精性脂肪性肝病治疗价值的Meta分析

侯捷; 刘立新

doi:10.3969/j.issn.1001-5256.2018.12.023

益生菌制剂对非酒精性脂肪性肝病治疗价值的Meta分析

DOI: 10.3969/j.issn.1001-5256.2018.12.023

侯捷,
刘立新

1. 山西医科大学第一医院消化科
2. 山西医科大学第一医院科研实验中心

基金项目:

高等学校优势学科攀升计划；山西省“1331工程”重点实验室立项支持平台项目；山西省重点研发计划(国际合作)项目(201603D421023)；

详细信息

中图分类号: R575.5
计量
- 文章访问数: 1667
- HTML全文浏览量: 14
- PDF下载量: 336
- 被引次数: 8
出版历程
- 出版日期: 2018-12-20

Effect of probiotics in treatment of nonalcoholic fatty liver disease: A Meta-analysis

Hou Jie,
Liu LiXin

Research funding:

摘要

摘要:
目的系统分析益生菌制剂对非酒精性脂肪性肝病（NAFLD）的治疗价值。方法检索2017年12月前在PubMed、The Cochrane Library、Embase、Medline、中国知网、万方及维普等数据库中公开发表的益生菌制剂治疗NAFLD的随机对照试验。对检索结果进行二次筛选、纳入研究风险偏移评估及信息提取后,采用RevMan 5. 3软件进行Meta分析。结果共纳入11项随机对照试验、599例NAFLD患者,结果显示:益生菌制剂可明显改善NAFLD患者的ALT（MD=-15. 23,95%CI:-19. 63～-10. 82,P <0. 000 01）、AST（MD=-17. 08,95%CI:-24. 23～-9. 92,P <0. 000 01）、GGT（MD=-20. 49,95%CI:-26. 23～-14. 74,P <0. 000 01）、TG（MD=-0. 12,95%CI:-0. 24～-0. 01,P=0. 04）、TC（MD=-0. 33,95%CI:-0. 56～-0. 11,P=0. 003）、HDL（MD=-0. 07,95%CI:...
- 非酒精性脂肪性肝病 /
- 有益菌种 /
- 治疗结果 /
- Meta分析
Abstract:
Objective To systematically analyze the value of probiotics in the treatment of nonalcoholic fatty liver disease (NAFLD) .Methods PubMed, The Cochrane Library, Embase, Medline, CNKI, VIP, and Wanfang Data were searched for randomized controlled trials (RCTs) on probiotics in the treatment on NAFLD published before December 2017. Secondary screening was performed for retrieval results, the risk of bias of the studies included was evaluated, and related data were extracted. Rev Man 5. 3 was used for the meta-analysis.Results A total of 11 RCTs with 599 NAFLD patients were included. The results showed that probiotics significantly improved the levels of alanine aminotransferase (mean difference [MD]=-15. 23, 95% confidence interval [CI]:-19. 63 to-10. 82, P < 0. 000 01) , aspartate aminotransferase (MD =-17. 08, 95% CI:-24. 23 to-9. 92, P < 0. 000 01) , gamma-glutamyl transpeptidase (MD =-20. 49, 95%CI:-26. 23 to-14. 74, P < 0. 000 01) , triglyceride (MD =-0. 12, 95% CI:-0. 24 to-0. 01, P = 0. 04) , total cholesterol (MD =-0. 33, 95% CI:-0. 56 to-0. 11, P = 0. 003) , high-density lipoprotein (MD =-0. 07, 95% CI:-0. 14 to-0. 01, P = 0. 03) , tumor necrosis factor-α (MD =-0. 38, 95% CI:-0. 52 to-0. 24, P < 0. 000 01) , and homeostasis model assessment of insulin resistance (MD =-0. 39, 95% CI:-0. 53 to-0. 24, P < 0. 000 01) . However, probiotics had no significant effect on body mass index (MD =-0. 73, 95% CI:-1. 91 to 0. 46, P = 0. 23) and low-density lipoprotein (MD =-0. 30, 95% CI:-0. 60 to 0. 01, P = 0. 06) .Conclusion Probiotics can significantly reduce the levels of liver aminotransferases, blood lipids, inflammatory factors, and insulin resistance in patients with NAFLD and thus exerts a certain therapeutic effect on NAFLD.
- non-alcoholic fatty liver disease /
- probiotics /
- treatment outcome /
- Meta analysis

HTML全文

参考文献(27)

[1] Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association. Guidelines for management of non-alcoholic fatty liver disease[J]. J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.

[2] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64 (1) :73-84.

[3] MIELE L, VALENZA V, La TORRE G, et al. Increased intestinal permeability and tight junction alterations in non-alcoholic fatty liver disease[J]. Hepatology, 2009, 49 (6) :1877-1887.

[4] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expen Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease:A 2018 update[J]. J Clin Hepatol, 2018, 34 (5) :947-957. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南 (2018年更新版) [J].临床肝胆病杂志, 2018, 34 (5) :947-957.

[5] SHUAI T, TIAN X, WANG XT, et al. A brief introduction of Jadad algorithm of interpreting discordant Meta analyses[J]. Chin J Evidbased Med, 2016, 16 (4) :492-496. (in Chinese) 帅婷, 田旭, 王新田, 等.冲突性Meta分析评价方法:Jadad法则简介[J].中国循证医学杂志, 2016, 16 (4) :492-496.

[6] SEPIDEH A, KARIM P, HOSSEIN A, et al. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease:A double-blind randomized clinical trial[J]. J Am Coll Nutr, 2016, 35 (6) :500-505.

[7] ALISI A, BEDOGNI G, BAVIERA G, et al. Randomized clinical trial:The beneficial effects of VSL#3 in obese children with nonalcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2014, 39 (11) :1276-1285.

[8] ALLER R, de LUIS DA, IZAOLA O, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients:A double blind randomized clinical trial[J]. Eur Rev Med Pharmacol Sci, 2011, 15 (9) :1090-1095.

[9] ESLAMPARAST T, POUSTCHI H, ZAMANI F, et al. Synbiotic supplementation in nonalcoholic fatty liver disease:A randomized, double-blind, placebo-controlled pilot study[J]. Am J Clin Nutr, 2014, 99 (3) :535-542.

[10] FAMOURI F, SHARIAT Z, HASHEMIPOUR M, et al. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents[J]. Pediatr Gastroenterol Nutr, 2017, 64 (3) :413-417.

[11] MALAGUARNERA M, VACANTE M, ANTIC T, et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis[J]. Dig Dis Sci, 2012, 57 (2) :545-553.

[12] VAJRO P, MANADATO C, LICENZIATI MR, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity related liver disease[J]. J Pediatr Gastroenterol Nutr, 2011, 52 (6) :740-743.

[13] WONG VW, WON GL, CHIM AM, et al. Treatment of nonalcoholic steatohepatitis with probiotics. Aproof-of-concept study[J].Ann Hepatol, 2013, 12 (2) :256-262.

[14] SHI BS. Effect of live combined Bifidobacterium and Lactobacillus tablets in improving nonalcoholic fatty liver disease[J]. Chin J Prev Contr Chron Dis, 2017, 25 (5) :387-390. (in Chinese) 史保生.双歧杆菌乳杆菌三联活菌片对非酒精性脂肪性肝病的改善作用[J].中国慢性病预防与控制, 2017, 25 (5) :387-390.

[15] YAO HX, CHEN WX, CHEN W, et al. Clinical study of probiotics in treatment of non-alcoholic fatty liver disease[J]. Chin J Gastroenterol and Hepatol, 2013, 22 (3) :221-223. (in Chinese) 姚惠香, 陈维雄, 陈玮, 等.益生菌治疗非酒精性脂肪性肝病的临床研究[J].胃肠病学和肝病学杂志, 2013, 22 (3) :221-223.

[16] ZHAO QW, LYU DX. Probiotics for non-alcoholic fatty liver disease intervention effect[J]. China Mod Doct, 2016, 54 (8) :29-33. (in Chinese) 赵庆卫, 吕道仙.益生菌对非酒精性脂肪性肝病的干预作用[J].中国现代医生, 2016, 54 (8) :29-33.

[17] LIU XY, KONG GM, QIAN F, et al. Advances in research on probiotics for the treatment of inflammatory bowel disease[J]. Clin J Med Offic, 2018, 46 (7) :840-842. (in Chinese) 刘心意, 孔桂美, 钱锋.益生菌治疗炎症性肠病研究进展[J].临床军医杂志, 2018, 46 (7) :840-842.

[18] ZHAO WT, LIN M, JIAO XH, et al. Comparative study of probiotics combined with triple therapy in the treatment of Helicobacter pylori infection in both spouses[J]. Clin J Med Offic, 2018, 46 (2) :191-193. (in Chinese) 赵文涛, 林苗, 焦小红, 等.配偶双方感染幽门螺杆菌采用益生菌联合三联疗法进行同时治疗与单方治疗疗效对比研究[J].临床军医杂志, 2018, 46 (2) :191-193.

[19] PAOLELLA G, MANDATO C, PIERRI L, et al. Gut-liver axis and probiotics:Their role in non-alcoholic fatty liver disease[J].World J Gastroenterol, 2014, 20 (42) :15518-15531.

[20] CHANG Y, LI H. The role of gut microbiota in thedevelopment and progression of nonalcoholic steatohepatitis[J]. J Clin Hepatol, 2018, 34 (6) :1343-1346. (in Chinese) 常越, 李海.肠道菌群与非酒精性脂肪性肝炎发生发展的关系[J].临床肝胆病杂志, 2018, 34 (6) :1343-1346.

[21] CHEN Z, HAN CK, PAN LL, et al. Serum alanine aminotransferase independently correlates with intrahepatic triglyceride contents in obese subjects[J]. Dig Dis Sci, 2014, 59 (10) :2470-2476.

[22] SATOH H, SAIJO Y, YOSHIOKA E, et al. Helicobacter Pylori infection is a significant risk for modified lipid profile in Japanese male subjects[J]. Atheroscler Thromb, 2010, 17 (10) :1041-1048.

[23] FEDERICO A, DALLIO M, GODOS J, et al. Targeting gut-liver axis for the treatment of non-alcoholic steatohe-patitis:translational and clinical evidence[J]. Transl Res, 2016, 167 (1) :116-124.

[24] SHIDA K, NOMOTO K. Probiotics as efficient immunpotentiators:Translational role in cancer prevention[J]. Indian Med Res, 2013, 138 (5) :808-814.

[25] FUKUDA S, TOH H, HASE K, et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate[J].Nature, 2011, 469 (7331) :543-547.

[26] YAO XM, QU JG, LIN AB, et al. Effect of probiotics on non-alcoholic fatty liver disease[J]. J Int Pham Res, 2014, 41 (5) :548-551, 558. (in Chinese) 姚晓敏, 曲均革, 林爱斌, 等.益生菌作用治疗非酒精性脂肪肝[J].国际药学研究杂志, 2014, 41 (5) :548-551, 558.

[27] BAI LM, ZHENG PY, ZHANG J, et al. Effects of cholesterollowering probiotics on the metabolism of bile acid in a rat model of non-alcoholic fatty liver disease[J]. Chin J Microbiol Immunol, 2016, 36 (2) :110-116. (in Chinese) 白利梅, 郑鹏远, 张军, 等.降脂益生菌对非酒精性脂肪肝大鼠胆汁酸代谢的影响及机制[J].中华微生物学和免疫学杂志, 2016, 36 (2) :110-116.

施引文献

期刊类型引用(5)

1.	许俊翱，黄艳雯，金满春. 水飞蓟素治疗临床肝病的疗效和不良反应分析. 系统医学. 2024(20): 66-69 . 百度学术
2.	万丽红，张静，陈爽，赵萍. 替诺福韦酯联合复方益肝灵片对肺结核合并HBV携带患者免疫功能及肝肾功能的影响. 临床和实验医学杂志. 2023(18): 1938-1942 . 百度学术
3.	管斌，朱建荣. 水飞蓟宾预防抗结核药物所致肝损伤的效果及安全性Meta分析. 中国热带医学. 2021(05): 496-500 . 百度学术
4.	赵红，吕芳芳，桑荣霞，王晓忠，李志惠，谢雯. 水飞蓟宾胶囊治疗药物性肝损伤的临床疗效. 甘肃医药. 2021(06): 490-493 . 百度学术
5.	金小琳，杨智彬，詹淑华，朱丹，何海英，殷水泽，马世武. 1501例初治住院结核病患者肝功能异常的影响因素. 中华实验和临床感染病杂志(电子版). 2020(05): 394-400 . 百度学术